Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2010 (2010), Article ID 708931, 8 pages
Review Article

Revisiting Estrogen: Efficacy and Safety for Postmenopausal Bone Health

Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada M5S 3E2

Received 1 February 2010; Accepted 26 April 2010

Academic Editor: Annie Kung

Copyright © 2010 Sandra M. Sacco and Wendy E. Ward. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The rapid decline in endogenous estrogen production that occurs during menopause is associated with significant bone loss and increased risk for fragility fracture. While hormone therapy (HT) is an effective means to re-establish endogenous estrogen levels and reduce the risk of future fracture, its use can be accompanied by undesirable side effects such as stroke and breast cancer. In this paper, we revisit the issue of whether HT can be both safe and effective for the prevention of postmenopausal bone loss by examining standard and alternative doses and formulations of HT. The aim of this paper is to continue the dialogue regarding the benefits and controversies of HT with the goal of encouraging the dissemination of-up-to date evidence that may influence how HT is viewed and prescribed.